A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolera Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosi
|Effective start/end date||4/1/22 → 3/31/27|
- RIVER 3 RENAL CORP
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.